Regulatory News:
ASIT biotech (ASIT - BE0974289218) (BSE:ASIT) (Paris:ASIT), a clinical stage biopharmaceutical company focused on the research, development and future commercialization of breakthrough immunotherapy products for the treatment of allergies, today announces that it has received a transparency notification dated 4 January, 2019, the result of which is - as a result of which people don’t act anymore in concert and the threshold of participation of 5% isn’t crossed anymore.
The statement dated 4 January 2019 notably includes the following information:
- Purpose of the notification
End of a concerted action agreement
- Notification by
People acting in concert
- Person subject to the notification requirement
Chagral Invest SPRL : 523, Avenue Louise – 1050 Bruxelles
3T
Finance SA : 6B bt7, Avenue Lloyd George – 1000 Bruxelles
- Date of the transaction
December 27th, 2018
- Threshold crossed (%)
The threshold of 5% is crossed
- Denominator
A total of 18,396,848 voting rights
- Details of the notification
A) Voting rights | Previous notification | After the transaction | ||||||||
# voting rights | # voting rights | % of voting rights | ||||||||
Holders of voting rights |
Attached | Non- |
Attached | Non- | ||||||
CHAGRAL INVEST SPRL | 406,913 | 2.21% | ||||||||
3T FINANCE SA | 671,074 | 3.65% | ||||||||
Sub-total | ||||||||||
TOTAL |
- Chain of controlled companies through which the participation is actually held
CHAGRAL INVEST and 3T FINANCE SA are not controlled within the meaning of Articles 5 and 7 of the Company Code
- This notification is available on ASIT biotech’s website, in the Documentation / Regulated information section:
https://www.asitbiotech.com/investors/documentation
***
About ASIT biotech
ASIT biotech is a Belgian clinical stage biopharmaceutical company focused on the development and future commercialization of a range of breakthrough immunotherapy products for the treatment of allergies. Thanks to its innovative ASIT+™ technology platform, ASIT biotech is currently the only developer of allergy immunotherapy (AIT) product candidates consisting of a unique mixture of highly purified natural allergen fragments in an optimal size selection. This innovation results in a short treatment, expected to improve patient compliance and real-life effectiveness. ASIT biotech’s product pipeline contains three novel ASIT+™ product candidates targeting respiratory allergies with the highest prevalence (i.e. grass pollen: gp-ASIT+™ and house dust mite: hdm-ASIT+™), and food allergies (peanut allergy: pnt-ASIT+™) that could significantly expand the current immunotherapy market. The Company believes that its innovative ASIT+™ platform is flexible and would be applicable across a range of allergies.
ASIT biotech has a headcount of 26 staff members, at its headquarters in Brussels and a laboratory in Liège, Belgium.
Further information can be found at www.asitbiotech.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190107005762/en/